23 October – Webinar in connection with Q3 interim report
Alligator hosted a webinar and conference call for investors, analysts on 23 October 2025 where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the interim report. The presentation was followed by a Q&A session.
The call was held in English. Attendees can request a reply at ir@alligatorbioscience.com.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Alligator Bioscience AB reports financial results for Q3 2025 and provides a business update
Upcoming rights issue of approx. SEK 120 million (gross), providing 6–9 months of financial runway during 2026, announced 22 October S …
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis …
Alligator Bioscience carries out a rights issue of units of approximately SEK 120 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …